Outcomes | Group | Odds ratio | 95% CI | p value |
---|
Hospital mortality |
Crude | Non-AF | Ref | | |
| New-onset AF | 1.46 | 1.32–1.62 | < 0.001 |
Model 1 | Non-AF | Ref | | |
| New-onset AF | 1.46 | 1.30–1.64 | < 0.001 |
Model 2 | Non-AF | Ref | | |
| New-onset AF | 1.61 | 1.41–1.85 | < 0.001 |
Crude | Preexisting AF | Ref | | |
| New-onset AF | 0.88 | 0.77–0.99 | 0.029 |
Model 1 | Preexisting AF | Ref | | |
| New-onset AF | 1.31 | 1.15–1.49 | < 0.001 |
Model 2 | Preexisting AF | Ref | | |
| New-onset AF | 1.17 | 1.01–1.35 | 0.034 |
- Model 1 was adjusted by: age, gender, type of intensive care unit, hypertension, diabetes, coronary heart diseases, congestive heart failure, hyperlipidemia, chronic obstructive pulmonary disease (COPD), cerebral infarction, pulmonary embolism, sepsis, and hypothyroidism; Model 2 was adjusted by: except variables in model 1, the following have been added: Sequential Organ Failure Assessment(SOFA) score, laboratory tests performed on admission, including white blood cells (WBC), hemoglobin (HB), serum creatinine (Scr), and medications during hospitalization, including β blockers, statin, amiodarone, Non-dihydropyridine calcium channel blocker (CCB), digoxin, warfarin
- AF atrial fibrillation, Ref reference